124 results
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
9 May 24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:08pm
more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
9 May 24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:08pm
) in collaboration with the NHMRC Clinical Trials Centre at the University of Sydney Lisata funded (LSTA eligible for ~43% rebate on all qualified R&D expenses
8-K
EX-99.2
3xy7i3uvrz 45
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
8-K
EX-99.1
dtvc0dg
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
8-K
EX-99.2
jna2ikqmr
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
2p7ey 3huut2u1ms
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.2
tiryxsld immkzl
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
xxr8t
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
m4snucaphe10izs
11 Jul 23
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
4:01pm
8-K
EX-99.2
itwdc40dap3i
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
v7suh 3mg
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm